The Board of Directors and Management of GlaxoSmithKline Consumer Nigeria Plc, has approved the appointment of Debra Mallowah, General Manager, CSK Consumer Healthcare East Africa as a non-executive director.
Basel Nizameddin, Business Development & Strategy Director, CSK Consumer Healthcare, Middle East & Africa, has also been alongside Mallowah as a non-executive director.
About Mallowah
Mallowah is a highly-accomplished leader with a wealth of experience in consumer-packaged goods gained in leading multi-national companies across sub-Sahara Africa. She has a proven track record of delivering growth at international, regional and local levels.
She started her career as a corporate marketing executive with the Institute of Advanced Technology (IAT), Kenya before joining International Distillers Kenya Limited, Kenya as Brand Manager and subsequently British American Tobacco (BAT) Regional Office, Eastern Africa as Area Product Manager. Mallowah •pined Diageo East Africa in 2002 as Marketing Manager, Core Brands and rose to increasing levels of responsibilities in the Diageo group in Kenya, East Africa, UK including roles as Marketing Director Kenya and Group Marketing & Innovation Director, East Africa.
In July 2013, Mallowah joined Unilever Africa as Vice President before joining CSK in 2018 as General Manager, East Africa in the Consumer Healthcare business. Mallowah sits on the Advisory Council of Women’s World Banking and is a member of the Africa Leadership Network. She served as Advisory Council member of the Africa Retail Congress and was honored by the Marketing Society with a warrior award for building and driving growth of world class brands in the region.
Mallowah holds a Bachelor of Commerce (B.Comm) Honours degree from the University of Nairobi, Kenya and an Advanced Management Program (AMP) from IESE, University of Navarro, Spain.
About Nizameddin
Nizameddin is a highly driven and top performing senior executive with over 22 years’ cognate experience within the Pharmaceutical & Consumer Healthcare industries in top tier 1 multinational companies across Middle East & Africa, targeting diversified consumers and patients’ segments.
Nizameddin started his career in 1995 as a medical representative with Eli Lilly before joining Novartis Consumer Health. He would later join Nestle Nutrition in 2000 where he held increasing levels of responsibilities including General Manager Iran, Business. In 2010, he joined Pfizer Nutrition as Business Strategy Director-Africa & Middle East and later General Manager Gulf and Yemen. He was to continue in that role when Nestle acquired Pfizer Nutrition until June 2014 when he became the Operating Unit Head, Middle East of Norvartis Consumer Health. Following the JV between Novartis and CSK Consumer Healtthcare in 2015, Nizameddin became the General Manager, Gulf, Iran and Near East of CSK Consumer Healthcare. He was appointed the Strategy & Business Development Director of CSK Consumer Healthcare Midle East and Africa in January 2018
Nizameddin is a speaker and active member of The Economist Corporate NetworkMENA and was in the past a member of the International Association of IF Manufacturers (IFM), representing Pfizer globally and the Global Marketing and Innovation Board at Pfizer Nutrition. He holds Bachelor of Science in Pharmacy from the Damascus University.
The company had released its financial statements for the period ended Q1 March 31st 2018.
The company reported Revenue of ₦4.21 billion for the period ended March 2018 compared to ₦3.85 billion reported for the period ended March 2017. This represents a 9% increase for the comparative period in 2017.
Profit before tax was ₦368.99 million for the period ended March 2018 compared to a ₦8.26 million loss before tax reported for the period ended March 2017.
The group’s profit after tax for the period ended March 2018 ₦258.29 million compared to ₦8.26 million loss after tax reported March 2017.
GlaxoSmithKline Consumer Nigeria Plc was on Monday, August 27, trading at GlaxoSmithKline Consumer Nigeria Plc at the Nigerian Stock Exchange (NSE).
The company is a science-led global healthcare company with a special purpose to help people do more, feel better and live longer.
